Avenue Therapeutics, INC. (ATXI) — 8-K Filings

8-K Filings (21)

• Avenue Therapeutics Files 8-K on Shareholder Votes — Dec 31, 2025 Risk: low
  Avenue Therapeutics, Inc. filed an 8-K on December 30, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's
• 8-K Filing — Nov 18, 2025
• 8-K Filing — Nov 12, 2025
• Avenue Therapeutics Files 8-K on Agreements and Acquisitions — Apr 30, 2025 Risk: medium
  On April 24, 2025, Avenue Therapeutics, Inc. filed an 8-K report detailing several material events. These include entering into and terminating a material defin
• Avenue Therapeutics Faces Delisting Notice — Mar 17, 2025 Risk: high
  Avenue Therapeutics, Inc. filed an 8-K on March 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
• Avenue Therapeutics Files 8-K — Mar 7, 2025 Risk: low
  Avenue Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting other events and financial statements. The company is incorporated in Delaware and its princi
• Avenue Therapeutics Faces Nasdaq Delisting Warning — Nov 29, 2024 Risk: high
  Avenue Therapeutics, Inc. announced on November 26, 2024, that it received a notice from The Nasdaq Stock Market LLC regarding its failure to meet the minimum b
• Avenue Therapeutics Appoints New CMO, CDO, and Directors — Sep 27, 2024 Risk: medium
  Avenue Therapeutics, Inc. announced on September 23, 2024, the appointment of Dr. James R. Scopa as Chief Medical Officer and Dr. Robert L. Smith as Chief Devel
• Avenue Therapeutics Appoints Dr. James N. Woody as CMO — Jun 26, 2024 Risk: medium
  Avenue Therapeutics, Inc. announced on June 24, 2024, the appointment of Dr. James N. Woody as Chief Medical Officer and a member of the Board of Directors. Dr.
• Avenue Therapeutics Files 8-K Report — May 23, 2024 Risk: low
  On May 21, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing an "Other Event." The filing does not disclose specific details about the event itself,
• Avenue Therapeutics Files 8-K on Financials — May 15, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhi
• Avenue Therapeutics Enters Material Definitive Agreement — May 13, 2024 Risk: medium
  Avenue Therapeutics, Inc. announced on May 10, 2024, that it entered into a Material Definitive Agreement. The company, incorporated in Delaware with its princi
• Avenue Therapeutics Files 8-K with Key Agreements and Equity Sales — May 1, 2024 Risk: medium
  On May 1, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engaged in
• Avenue Therapeutics Files 8-K: Security Holder Rights & Bylaws Modified — Apr 26, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on April 26, 2024, reporting material modifications to security holder rights and other events as of April 25, 2024. The
• Avenue Therapeutics Faces Delisting Notice — Mar 29, 2024 Risk: high
  Avenue Therapeutics, Inc. filed an 8-K on March 29, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of March 26, 2024. Th
• Avenue Therapeutics Files 8-K on Financials — Mar 18, 2024 Risk: low
  On March 18, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statemen
• Avenue Therapeutics Closes $10M Public Offering — Mar 15, 2024 Risk: medium
  On March 11, 2024, Avenue Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised app
• Avenue Therapeutics Files 8-K on Security Holder Vote — Mar 8, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on March 8, 2024, reporting that a matter was submitted to a vote of its security holders on March 6, 2024. The filing do
• Avenue Therapeutics Amends Bylaws, Changes Fiscal Year — Feb 23, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on February 23, 2024, reporting an event that occurred on February 20, 2024. The filing indicates amendments to its Artic
• Avenue Therapeutics Files 8-K on Shareholder Vote Submission — Jan 12, 2024
  Avenue Therapeutics, Inc. filed an 8-K on January 12, 2024, reporting an event that occurred on January 9, 2024, related to the submission of matters to a vote
• Avenue Therapeutics Sells New Equity, Dilution Risk for ATXI Holders — Jan 8, 2024
  Avenue Therapeutics, Inc. (ATXI) filed an 8-K on January 8, 2024, reporting a material definitive agreement and unregistered sales of equity securities on Janua

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX